principles Flashcards
define diabetes
hyperglycasemia above a fasting glucose of 7mmol/L
-> a threshold set in relation to risk of diabetic retinopathy
main mechanism of metformin
inhibits complex 1 in respiratory chain causing a fall in cellular ATP, results in -
- reduction in hepatic gluconeogenesis
- activation of AMP-activated protein kinase (AMPK)
- increases gut glucose utilisation + metabolism
what organs does metformin highly concentrate in?
intestine, liver, kidney
Organic Cation Transporters (OCTs) are found here which metformin needs to get into cells as its hydrophillic
benefits of metformin
- weight neutral / negative
- v cheap
- potent glucose monitoring
- generally well tolerated
- CV benefit ish
metformin side effects
GI upset - diarrhoea, nausea, abdo pain (20%)
lactic acidosis - in liver disease / renal failure, metformin increase lactate
reduced B12 absorption
*modified release formula available (better tolerated)
how can metformin side effect be reduced?
starting - should be titrated up slowly to reduce incidence of GI side effects
sulphonylureas MoA
act directly on pancreatic beta-cells to increase insulin secretion
glucose independent = insulin secretion even when not needed (glucose low/norma) –> results in HYPOglycaemia
suphonylurea side effects
hypoglycaemia risk
weight gain
cheap but lack of CV benefit (compared to metformin)
thiazolidinediones side effects
weigh gain
fluid retention - peripheral oedeam
fracture risk - increase fat in bones + decrease bone density
thiazolidinediones (TZDs) MoA
TZD = pioglitazone
PPAR-gamma rceptor agonist
reduces peripheral insulin resistance (insulin sensitiser)
increase fat mass - “suck out” fat from liver, pancreas + muscle
increases adiponectin + reduced inflam cytokines
Dipeptidyl peptidase-4 (DDP-4) inhibitors
increases levels of incretins (GLP-1 + GIP) by decreasing their peripheral breakdown
–> increase insulin secretion but only when needed (unlike sulphonylureas)
well tolerated - minimal SE
moderate cost
weight neutral
weak glucose lowering
GLP-1 like molecules
promote insulin secretion when needed (glucose dependent)
lowers glucagon
reduces appetite (weight loss) + gastric emptying + BP
potent at glucose lowering
expensive
SE - N+V, gallstones
(subcutaneous)
SGLT-2 inhibitors MoA
inhibits reabsorption of glucose in the kidney
–> makes you pee sugar - increase thrush risk
(oral)
describe the structure of insulin
polypeptide composed of an A chain + B chain linked by disulfide bonds
how is insulin synthesised?
in the rough endoplasmic reticulum of beta-cells
preproinsulin -> proinsulin + single peptide -> C-peptide + insulin
C-peptide = no function preproinsulin = single chain preprohotmone
what do alpha-cells of the pancreatic islets secrete?
glucagon
what do delta-cells of the pancreatic islets secrete?
secrete somatostatin
comment on insulins physiological window
NARROW
death by causing hypoglycaemic coma
how does glucose enter pancreatic beta-cells?
via GLUT2 glucose transporter
what is glucose phosphorylated by in the pancreatic beta cell?
glucokinase